A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are three cash-producing companies to steer clear of and a few better alternatives.
Gorman-Rupp (GRC)
Trailing 12-Month Free Cash Flow Margin: 10%
Powering fluid dynamics since 1934, Gorman-Rupp (NYSE:GRC) has evolved from its Ohio origins into a global manufacturer and seller of pumps and pump systems.
Why Does GRC Worry Us?
- Sales trends were unexciting over the last two years as its 7.1% annual growth was below the typical industrials company
- Estimated sales growth of 3.8% for the next 12 months implies demand will slow from its two-year trend
- Free cash flow margin shrank by 4.2 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
At $36.58 per share, Gorman-Rupp trades at 17.1x forward P/E. If you’re considering GRC for your portfolio, see our FREE research report to learn more.
Addus HomeCare (ADUS)
Trailing 12-Month Free Cash Flow Margin: 7.4%
Serving approximately 66,000 clients across 22 states with a focus on "dual eligible" Medicare and Medicaid beneficiaries, Addus HomeCare (NASDAQ:ADUS) provides in-home personal care, hospice, and home health services to elderly, chronically ill, and disabled individuals.
Why Are We Wary of ADUS?
- Revenue base of $1.21 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Free cash flow margin has shown no improvement over the last five years
Addus HomeCare’s stock price of $111.20 implies a valuation ratio of 18x forward P/E. Read our free research report to see why you should think twice about including ADUS in your portfolio.
Avantor (AVTR)
Trailing 12-Month Free Cash Flow Margin: 10%
With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.
Why Are We Hesitant About AVTR?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Demand will likely be weak over the next 12 months as Wall Street expects flat revenue
- Inability to adjust its cost structure while its revenue declined over the last two years led to a 3 percentage point drop in the company’s adjusted operating margin
Avantor is trading at $12.96 per share, or 11.8x forward P/E. To fully understand why you should be careful with AVTR, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.